Shaping the future of mental healthcare

The Isala Fund supports innovative scientific research into the therapeutic use of psychedelic substances in Belgium.

Our mission centers on advancing knowledge and accessibility in the field of psychedelic-assisted therapy for the benefit of those in need.

Introducing our
activities

We run biannual 3-day workshops for clinicians on clinical psychedelic research and psychological support. We develop resources for setting up studies, offer consultancy and supervision, and support research projects through funding calls when possible.

We run biannual 3-day workshops for clinicians on clinical psychedelic research and psychological support. We develop resources for setting up studies, offer consultancy and supervision, and support research projects through funding calls when possible.

We run biannual 3-day workshops for clinicians on clinical psychedelic research and psychological support. We develop resources for setting up studies, offer consultancy and supervision, and support research projects through funding calls when possible.

Workshops

offering a theoretical and experiential Fund to work on psychedelic-assisted studies for research teams led by international experts.

Clinical Trials

offering a theoretical and experiential Fund to work on psychedelic-assisted studies for research teams led by international experts.

Consultancy & supervision

Consultancy and supervision for psychedelic research teams

Introducing our
team

A passionate team with expertise in psychotherapy, psychiatry, psychology, psychedelic research, business development, and economics, working to advance psychedelic research in Belgium for better patient treatments.

Koslowski Michael

Core member

Koslowski Michael

Core member

Michael Koslowski is a physician, psychiatrist, and psychotherapist. He is affiliated with the psychedelic research group at Charité University in Berlin. Michael played a key role in establishing Germany's first clinical study on psilocybin-assisted therapy for treatment-resistant depression, where he has worked as a therapist over the past five years. He is also involved in the development of psychedelic therapy clinical studies in France.

Mathieu Seynaeve

Core Member

Mathieu Seynaeve

Core Member

Mathieu is a psychiatrist specializing in psychedelic research and drug development. He began as a Senior Research Associate in the Psychedelic Trials Group at King's College London and is now the Senior Medical Director and Head of Psychotherapy at Beckley Psytech, while completing his PhD on the psychological change mechanisms of 5-MeO-DMT. He also holds a master’s degree in Economics.

Laetitia Vanderijst

Core Member

Laetitia Vanderijst

Core Member

Laetitia Vanderijst is a psychologist and PhD candidate at the Université Libre de Bruxelles. In June 2022, she received an FNRS research fellowship to establish Belgium's first psilocybin-assisted therapy study at CHU Brugmann. This clinical trial, which began in March 2024, investigates the clinical efficacy and neurocognitive mechanisms associated with this therapeutic modality for severe alcohol use disorder.

Raphael Beaumond

Core Member

Raphael Beaumond

Core Member

Raphael Beaumond is an economist and electromechanical engineer committed to developing initiatives that sustainably improve quality of life for all. He designs and implements entrepreneurial projects that combine collective well-being, economic resilience, and data analysis.His work explores investment strategies and impact-driven innovation, with the ambition of equipping financial and political decision-makers with the tools needed to create informed societal value.

How to support
us

Join our community of supporters! Donate, volunteer, or share our work. Together, we can positively impact mental health in Belgium.